A fluoroquinolone antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Tosufloxacin (tosylate)

Item No. 21427

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid 4-methylbenzenesulfonate
CAS Number
115964-29-9
Molecular Formula
C19H15F3N4O3 • C7H8O3S
Formula Weight
576.5
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMSO: 30 mg/mlDMSO:PBS (pH 7.2) (1:2): 0.33 mg/mlEthanol: slightly soluble
λmax
221, 269, 341 nm
SMILES
O=C1C2=C(N=C(N3CCC(N)C3)C(F)=C2)N(C4=CC=C(F)C=C4F)C=C1C(O)=O.CC5=CC=C(S(O)(=O)=O)C=C5
InChi Code
InChI=1S/C19H15F3N4O3.C7H8O3S/c20-9-1-2-15(13(21)5-9)26-8-12(19(28)29)16(27)11-6-14(22)18(24-17(11)26)25-4-3-10(23)7-25;1-6-2-4-7(5-3-6)11(8,9)10/h1-2,5-6,8,10H,3-4,7,23H2,(H,28,29);2-5H,1H3,(H,8,9,10)
InChi Key
CSSQVOKOWWIUCX-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    100 mg

    $63

    Add

    250 mg

    $107

    Add

    500 mg

    $153

    Add

    1 g

    $274

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Tosufloxacin is a fluoroquinolone antibiotic. It has activity against diverse aerobic and anaerobic bacteria in vitro.1,2 Tosufloxacin is also effective against bacterial persisters, showing significant activity against S. aureus and uropathogenic E. coli persisters.3,4 As with many other quinolones, tosufloxacin use can be associated with significant side effects.5

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Espinoza, A.M., Chin, N.-X., Novelli, A., et al. Comparative in vitro activity of a new fluorinated 4-quinolone, T-3262 (A-60969). Antimicrob. Agents Chemother. 32(5), 663-670 (1988).

    2. Fernandes, P.B., Chu, D.T.W., Swanson, R.N., et al. A-61827 (A-60969), a new fluoronaphthyridine with activity against both aerobic and anaerobic bacteria. Antimicrob. Agents Chemother. 32(1), 27-32 (1988).

    3. Niu, H.Y., Cui, P., Yee, R., et al. A clinical drug library screen identifies tosufloxacin as being highly active against Staphylococcus aureus persisters. Antibiotics (Basel) 4(3), 329-336 (2015).

    4. Niu, H.Y., Cui, P., Shi, W., et al. Identification of Anti-Persister Activity against Uropathogenic Escherichia coli from a Clinical Drug Library. Antibiotics (Basel) 4(2), 179-187 (2015).

    5. Rubinstein, E. History of quinolones and their side effects. Chemotherapy 47 (Suppl. 3), 44-48 (2001).